IVVD - NASDAQ

Invivyd, Inc.

IVVD·NASDAQ

$1.13

+1.5%

HealthcareBiotechnology

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$150.25M

EPS-0.3000

P/E Ratio-3.77

Earnings Date08/13/2026

ivvd

Cash and Cash Equivalents

Last Annual Value

226.69M

3-Year CAGR

35%

5-Year CAGR

15%

10-Year CAGR

Adjust for Inflation

Invivyd, Inc. Competitors Analysis of Cash and Cash Equivalents

IVVD · NASDAQ

Company	Cash and Cash Equivalents	CAGR 3Y	CAGR 5Y	CAGR 10Y
Invivyd, Inc. NASDAQ:IVVD	226.69M	4.2%	-16.0%	N/A
OmniAb, Inc. NASDAQ:OABI	25.52M	16.0%	N/A	N/A
SELLAS Life Sciences Group, Inc. NASDAQ:SLS	71.89M	205.2%	27.4%	14.8%
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	28.49M	27.6%	2.6%	6.6%
Pyxis Oncology, Inc. NASDAQ:PYXS	15.42M	16.9%	-43.8%	N/A
Cassava Sciences, Inc. NASDAQ:SAVA	95.50M	-7.6%	-16.4%	17.7%
Vor Biopharma Inc. NASDAQ:VOR	396.49M	133.0%	27.0%	N/A
Sangamo Therapeutics, Inc. NASDAQ:SGMO	20.95M	-22.6%	-34.9%	-0.5%
Neonc Technologies Holdings, Inc. NASDAQ:NTHI	58.73K	22.6%	18.6%	N/A
C4 Therapeutics, Inc. NASDAQ:CCCC	74.60M	-16.2%	-0.4%	N/A
Insight Molecular Diagnostics Inc. NASDAQ:IMDX	11.58M	7.1%	-18.9%	1.3%

Invivyd, Inc. Fair Value Envelope

IVVD · NASDAQ

Our analysis suggests that IVVD has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.132, this represents a potential HIDDEN relative to our calculated worth for Invivyd, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.132

Related Guides

Blog Categories

Continue your IVVD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.